Retatrutide
Three signals. No final stamp.
From laboratory assays and mouse studies to early volunteers, larger trials and today’s open questions.
Journey published October 11, 2026 · Evidence reviewed 2026-10-11
- 01Three doors light upLY3437943 · Laboratory work reported 2022
- 02Before the human doorwayPreclinical mouse experiments · Reported 2022
- 03The first volunteer questionsHuman studies conducted 2019–2020
- 04The scale is not the whole storyPhase 2 studies · 2023–2025 publications
- 05The testing hall gets biggerPhase 3 · 2023–2026
- 06The stamp is still missingOctober–November 2026 trial analyses, regulatory decisions and conference reports
Today’s checkpoint
Phase 3 results have expanded the evidence. Retatrutide remains investigational; a successful trial is not an approval.
Open the medicine’s evidence profile · Other journeys
Documented milestones, not every unpublished experiment. The story is fictional; each chapter identifies the real study population and source.